Rogers Communications Inc. reported a 65% year-over-year increase in free cash flow for Q3 2026, driven mainly by asset sales and deferred capital expenditures. Despite facing competitive and regulatory pressures that impact subscriber growth and average revenue per user, the company maintains strong operational margins. Its undervalued sports assets, including the recent MLSE consolidation, present significant hidden value and potential for debt reduction through minority stake sales. Rogers trades at a steep valuation discount, making it an attractive buy for investors looking beyond short-term challenges.
Rogers Communications is the subject of this report, and for readers following the Technology sector, here is Pluang's market snapshot as of Oct 24, 2026 00:11 WIB: Out of 150 priced US Technology stocks tradable on Pluang, 81 rose and 68 fell today. Notable movers include FIVN (Five9 Inc) at USD 37.19 with a 1-day change of +5.95%, CRWD (Crowdstrike Holdings Inc) at USD 252.00 with a 1-day change of +5.91% and a Pluang order activity of 47% Sell / 53% Buy, and INFY (Infosys Limited) at USD 12.47 with a 1-day change of -5.67% and 100% Sell order activity. The most notable figure is the 5.95% gain of FIVN on the day.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
